Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Can Fite BiopharmaCANF 60 Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 60/100 and a GF Value™ of $5.90 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 835 Biotechnology companies, Can Fite Biopharma ranks worse than 119760.36% on this metric.
The historical rank and industry rank for Can Fite Biopharma's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Can Fite Biopharma's highest Days Sales Outstanding was 93.10. The lowest was 10.25. And the median was 51.68.
CANF's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.94 * Ranked among companies with meaningful Days Sales Outstanding only.
Can Fite Biopharma's Days Sales Outstanding
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Can Fite Biopharma (AMEX:CANF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Can Fite Biopharma Days Sales Outstanding Related Terms
Can Fite Biopharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Can Fite Biopharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Days Sales Outstanding falls into.
Can Fite Biopharma Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a Days Sales Outstanding of 0.00 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Can Fite Biopharma and its competitors. Over the past decade, Can Fite Biopharma's Days Sales Outstanding has ranged from 10.25 to 93.10. According to the industry distribution chart, Can Fite Biopharma ranks #999999 out of 835 companies in the Biotechnology industry.
Is Can Fite Biopharma's Days Sales Outstanding too high?
Can Fite Biopharma's current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 10.25 to a high of 93.10. Based on the distribution chart, Can Fite Biopharma ranks #999999 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #999999 out of 835 companies for Days Sales Outstanding. This places Can Fite Biopharma in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Historically, Can Fite Biopharma's own Days Sales Outstanding has ranged from 10.25 to 93.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Can Fite Biopharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.90, compared to a current price of $3.32 — trading 43.7% below its estimated fair value. The current Days Sales Outstanding is 0.00. Can Fite Biopharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $3.32 is trading 43.7% below its estimated GF Value™ of $5.90.
GuruFocus considers Can Fite Biopharma to be Possible Value Trap.
Key valuation signals for CANF:
Days Sales Outstanding: 0.00
GF Value™: $5.90 vs. price of $3.32 (43.7% below fair value)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score
Get the complete analysis for CANF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
